Xiaohui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaohui Chen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Miersalijiang Yasen
Department of Orthopedic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China
4 shared publications - Shengrong Lin
Department of Orthopedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China
3 shared publications - Xiaomin Xue
Department of Orthopedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China
3 shared publications - Yunbang Liang
Department of Orthopedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China
3 shared publications - Gang Rui
Department of Orthopedics, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China
2 shared publications Xianhui Zeng
Department of Infectious Diseases, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou 570206, China
2 shared publications
Latest Publications
- Open Access
- 11 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 117094
Penfluridol regulates p62 / Keap1 / Nrf2 signaling pathway to induce ferroptosis in osteosarcoma cells
- 11 July 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 177, 117094
Open AccessPenfluridol regulates p62 / Keap1 / Nrf2 signaling pathway to induce ferroptosis in osteosarcoma cells
- RetractionOpen Access
- 15 May 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (7) , 5333
Retraction Note: Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects
- 15 May 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (7) , 5333
RetractionOpen AccessRetraction Note: Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects
- 4 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111747
PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells
- 4 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111747
PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells
- 13 February 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 392, 110904
Trifluoperazine activates AMPK / mTOR / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells
- 13 February 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 392, 110904
Trifluoperazine activates AMPK / mTOR / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells
- 9 December 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 219, 115974
Inhibition of FABP5 attenuates inflammatory bowel disease by modulating macrophage alternative activation
- 9 December 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 219, 115974
Inhibition of FABP5 attenuates inflammatory bowel disease by modulating macrophage alternative activation
- Open Access
- 20 June 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (12) , 3893
Correction to: Experimental evidence of shikonin as a novel intervention for anti‑inflammatory effects
- 20 June 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (12) , 3893
Open AccessCorrection to: Experimental evidence of shikonin as a novel intervention for anti‑inflammatory effects
- Retracted
- 30 May 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (12) , 3547-3557
RETRACTED ARTICLE: Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects
Shikonin is a natural product with antioxidant and anti-inflammatory activities. The biological activity of shikonin is still not fully understood, as well as its association with innate immunity and immune and inflammatory bowel disease (IBD) in humans. In this study, the toxicity of shikonin on Raw264.7 cells was assayed by MTT, and polarization of inflammatory macrophages was determined by flow cytometry. The results showed that shikonin can inhibit the polarization of macrophages towards M1 type and significantly inhibited the production of NO in the concentration range of 0.5-1 mu M. In addition, after treatment with shikonin, the production of IL-1 beta and TNF-alpha was significantly decreased. After shikonin administration, the body weight loss and decrease of colon length were significantly suppressed in DSS-treated colitis C57BL/6 mice. The proinflammatory cytokines TNF-alpha and IL-1 beta in colonic homogenate were significantly decreased. Shikonin treatment resulted in a notable improvement in the histopathological manifestations in DSS-treated animals at 25/50 mg/kg. Meanwhile, we found that shikonin can regulate differentiation of T helper 17 cell (Th17)/regulatory T cell (Treg), thereby regulating the balance of Th17/Treg cells and exerting an anti-inflammatory effect in IBD animal models. In conclusion, we found that shikonin protects against DSS-induced acute colitis by, among other things, reducing immune cell infiltration, polarizing macrophages, and regulating Th17/Treg differentiation, as well as by downregulating the release of inflammatory cytokines. These findings showed that shikonin can improve inflammation by affecting macrophage polarization. Our experimental data provide experimental evidence and theory basis for research on anti-inflammatory effects for the shikonin as health or functional food.
- 30 May 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (12) , 3547-3557
RetractedRETRACTED ARTICLE: Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects
Shikonin is a natural product with antioxidant and anti-inflammatory activities. The biological activity of shikonin is still not fully understood, as well as its association with innate immunity and immune and inflammatory bowel disease (IBD) in humans. In this study, the toxicity of shikonin on Raw264.7 cells was assayed by MTT, and polarization of inflammatory macrophages was determined by flow cytometry. The results showed that shikonin can inhibit the polarization of macrophages towards M1 type and significantly inhibited the production of NO in the concentration range of 0.5-1 mu M. In addition, after treatment with shikonin, the production of IL-1 beta and TNF-alpha was significantly decreased. After shikonin administration, the body weight loss and decrease of colon length were significantly suppressed in DSS-treated colitis C57BL/6 mice. The proinflammatory cytokines TNF-alpha and IL-1 beta in colonic homogenate were significantly decreased. Shikonin treatment resulted in a notable improvement in the histopathological manifestations in DSS-treated animals at 25/50 mg/kg. Meanwhile, we found that shikonin can regulate differentiation of T helper 17 cell (Th17)/regulatory T cell (Treg), thereby regulating the balance of Th17/Treg cells and exerting an anti-inflammatory effect in IBD animal models. In conclusion, we found that shikonin protects against DSS-induced acute colitis by, among other things, reducing immune cell infiltration, polarizing macrophages, and regulating Th17/Treg differentiation, as well as by downregulating the release of inflammatory cytokines. These findings showed that shikonin can improve inflammation by affecting macrophage polarization. Our experimental data provide experimental evidence and theory basis for research on anti-inflammatory effects for the shikonin as health or functional food.